<DOC>
	<DOCNO>NCT01365611</DOCNO>
	<brief_summary>This non-randomized , open label study healthy male female volunteer . A single intranasal dose 30 mg ketorolac tromethamine administer subject Days 1 6 ; addition , subject receive daily intranasal dose 200 Âµg fluticasone propionate Days 2-6 . Subjects remain resident Clinical Unit even Day 1 morning Day 2 even Day 5 morning Day 7 , make ambulatory visit Clinical Unit morning Days 3-5 . A post study medical perform within 7 day study completion . The objective study assess effect chronic administration fluticasone propionate pharmacokinetics intranasal ketorolac healthy male female subject .</brief_summary>
	<brief_title>Open Label Study Assess Pharmacokinetics Intranasal Ketorolac Tromethamine Following Fluticasone Propionate Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<criteria>Male female volunteer age 18 60 year inclusive Female subject child bear potential must negative urine pregnancy test prior entry study must breastfeed All male subject female partner child bear potential must consent use medically acceptable method contraception ( oral implant contraceptive hormone , intrauterine device surgical sterilization plus condom diaphragm spermicidal agent ) throughout study period Subject must give sign informed consent Subject within 20 % normal weight his/her height body build accord table `` Desirable Weights Men Women '' ( Metropolitan Life Insurance Co. 1999 ) Subject 's medical history consider normal , clinically significant abnormality Subject consider good health opinion Investigator determine prestudy physical examination clinically significant abnormality , vital sign within normal range electrocardiogram ( ECG ) clinically significant abnormality Subject 's pre study clinical laboratory finding within normal range outside normal range deem clinically significant opinion Investigator Subject bilateral patent nasal airway screen Day 1 assess Investigator Subject body weight least 60 kg Subject clinically significant illness 4 week screen Subject use prescribed medication 3 week prior dose overthecounter preparation 7 day prior dose , except paracetamol allow 48 h prior dose . However , use multivitamins oral contraceptive permit Subject significant history drug/solvent abuse , positive drug abuse ( DOA ) test screen Subject history alcohol abuse currently drink excess 28 unit per week ( male ) 21 unit per week ( female ) Subject current user tobacco history smoking past 5 year Subject opinion Investigator suitable participate study Subject participate clinical study investigational drug/device within 3 month prior dose Subject positive result human immunodeficiency virus ( HIV ) screen , hepatitis B screen hepatitis C screen Subject serious adverse reaction significant hypersensitivity drug Subject donate 500 mL blood within 3 month prior screen Subject history coexist nasal polyp , nonsteroidal antiinflammatory drug ( NSAID ) sensitivity asthma Subject allergic reaction aspirin NSAIDs Subject current upper respiratory tract infection respiratory tract condition could interfere absorption nasal spray assessment adverse event ( AEs ) Any suspicion rhinitis medicamentosa ( chronic daily use topical decongestant ) Subject use monoamine oxidase inhibitor 14 day prior study entry Subject active peptic ulcer disease , gastrointestinal bleeding perforation , history peptic ulcer disease gastrointestinal bleeding Subject anemia due unexplained known gastrointestinal bleeding Subject history asthma chronic pulmonary disorder Subject renal impairment risk renal failure due volume depletion Subject previous history nasal surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>